Tlando Improves Atopic Dermatitis in Hypogonadal Men: 18-Month Cohort Study
Reading Time: < 1 minute Introduction Hypogonadism, characterized by deficient testosterone production, affects approximately 4-5 million American men, with prevalence rising sharply after age 40 due to age-related androgen decline. This endocrine disruption not only impairs sexual function, muscle mass, and bone density but also influences dermatological health. Atopic dermatitis (AD), commonly known as eczema, manifests as chronic pruritic inflammation, impacting 10-15% of U.S. adult males. Emerging evidence suggests low serum testosterone correlates with exacerbated AD severity, potentially via impaired skin barrier function and dysregulated Th2-mediated inflammation. Tlando (testosterone undecanoate) oral capsules, approved by the FDA in 2019 for hypogonadism, offer a novel non-injectable delivery...


